Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azacitidine - AbbVie

Next Previous
Search
Drug Profile

Azacitidine - AbbVie

Latest Information Update: 16 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 16 Jan 2025 Phase-III development is still ongoing for Myelodysplastic syndromes (Combination therapy, First-line therapy) in Czech Republic, Belgium, Poland, United Kingdom, Spain, Japan and China (IV, SC), (NCT04401748)
  • 09 Feb 2022 Phase-II clinical trials in Acute myeloid leukaemia (Treatment-naive, In adults, In the elderly) in USA (IV) (NCT04905810)
  • 10 Sep 2020 Phase-III clinical trials in Myelodysplastic syndromes (Combination therapy, First-line therapy) in Australia, Austria, Belgium, Canada, China, Czech Republic, Germany, France, Hungary, Italy, Japan, South Korea, Netherlands, Poland, Puerto Rico, Russia, Spain, Turkey, Taiwan, United Kingdom (SC) (NCT04401748; EudraCT2020-000744-55)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top